Immune Pharmaceuticals Provides a Corporate Update
September 13, 2018 07:30 ET
|
Immune Pharmaceuticals, Inc.
Conference call with live audio webcast today, Thursday, September 13th at 8:30am EDT FORT LEE, N.J., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the...
Bertilimumab Granted Fast Track Designation for the Treatment of Bullous Pemphigoid
September 11, 2018 07:30 ET
|
Immune Pharmaceuticals, Inc.
Company to provide corporate update during conference call with live audio webcast on Thursday, September 13th at 8:30am EDT FORT LEE, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Immune...
Immune Pharmaceuticals Issues Statement on Former Chief Executive Officer
September 10, 2018 07:00 ET
|
Immune Pharmaceuticals, Inc.
FORT LEE, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for the...
Bertilimumab Granted Orphan Drug Designation for the Treatment of Bullous Pemphigoid
August 20, 2018 11:34 ET
|
Immune Pharmaceuticals, Inc.
ENGLEWOOD CLIFFS, N.J., Aug. 20, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for...
Immune Pharmaceuticals Postpones Special Meeting of Stockholders
August 02, 2018 16:05 ET
|
Immune Pharmaceuticals, Inc.
- Special Meeting of Stockholders scheduled for August 22, 2018 postponed - - Company plans to appeal Nasdaq delisting determination - ENGLEWOOD CLIFFS, N.J., Aug. 02, 2018 (GLOBE NEWSWIRE) --...
Immune Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for Bertilimumab for the Treatment of Bullous Pemphigoid
July 30, 2018 08:00 ET
|
Immune Pharmaceuticals, Inc.
ENGLEWOOD CLIFFS, N.J., July 30, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (OTCQB: IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for...
Immune Pharmaceuticals Receives Nasdaq Delisting Determination; Eligible to trade Over-the-Counter July 26, 2018
July 26, 2018 09:15 ET
|
Immune Pharmaceuticals, Inc.
ENGLEWOOD CLIFFS, N.J., July 26, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (Nasdaq:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing novel therapeutic agents for...
Immune Pharmaceuticals Announces Filing of Proxy Statement for Reverse Stock Split
July 17, 2018 08:30 ET
|
Immune Pharmaceuticals, Inc.
– Immune to hold Special Meeting of Stockholders Wednesday, August 22, 2018 – – Company encourages stockholders to vote in favor of the Board of Director’s suggested proposals – ENGLEWOOD CLIFFS,...
WuXi Biologics and Immune Pharmaceuticals Announce Late-phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody
July 09, 2018 07:00 ET
|
Immune Pharmaceuticals, Inc.
SHANGHAI, China and ENGLEWOOD CLIFFS, N.J., July 09, 2018 (GLOBE NEWSWIRE) -- WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end...
Immune Pharmaceuticals Announces Receipt of Nasdaq Listing Determination
June 08, 2018 08:30 ET
|
Immune Pharmaceuticals, Inc.
Company to Request Hearing ENGLEWOOD CLIFFS, N.J., June 08, 2018 (GLOBE NEWSWIRE) -- Immune Pharmaceuticals, Inc. (Nasdaq:IMNP) (“Immune” or the “Company”), a biopharmaceutical company developing...